STOCKS TELEGRAPH

Author: ST Staff

  • Has Cybin (CLXPF) Stock Risen Last Session For A Reason?

    Has Cybin (CLXPF) Stock Risen Last Session For A Reason?

    On Monday, Cybin Inc (OTCQB: CLXPF) closed at $1.6732, up 5.90 percent, and its day-range has been $1.7600 to $1.6000. Cybin stock surged 17.83% over the past month with average volume of 271.70K shares.

    The CLXPF stock gained 60.90% in the past three months while the average volume was 400.55K. The CLXPF stock has experienced an annual gain of 142.58%, reaching a high of $2.2350 with a market cap of $247.89M. CLXPF stock rose for positive results of a pre-clinical trial.

     What was that trial for?

    Cybin is one of the leading biotechnology companies focusing on the development of psychedelic therapeutics. CLXPF utilizes its patent-pending drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and potential treatment regimens to discover new treatments for mental illness.

    In the period beginning January 1, 2021, Cybin announced that Adelia Therapeutics Inc. (“Adelia”) has achieved certain milestones in relation to earn-outs.

    • Cybin, Cybin Corp., Cybin US Holdings Inc. (the “Acquirer”), a wholly-owned subsidiary of Cybin, and all previous Adelia shareholders agreed to meet the milestones in a contribution agreement dated December 4, 2020.
    • As part of various milestones in the earn-out process, positive pre-clinical results were achieved.
    • The results of the study indicated that proprietary deuteration modifications did not alter pharmacodynamic properties of multiple new chemical entities.
    • Furthermore, the deuterated analogs were as safe as their non-deuterated counterparts in in-vitro toxicity tests.
    • CLXPF believes that this preliminary evidence adds value to Cybin’s pipeline of novel, proprietary psychedelic molecules by showing their performance on certain important metrics is comparable to that of naturally occurring compounds.
    • CLXPF differentiates itself from psychedelic companies mainly by developing its own compounds.
    • In accordance with the terms of the Transaction Agreement, Adelia Shareholders will receive Class B common shares in the capital of the CLXPF upon meeting the relevant milestone.

    How will CLXPF handle it?

    In addition to the Class B Shares granted by Cybin (CLXPF) to the Adelia Shareholders, the Class B Shares may be exchanged for shares of Cybin in exchange for the Class B Shares (at the option of the shareholder and subject to customary adjustments).

    The Transaction Agreement provides that no Class B Shares can be exchanged before the first anniversary of the date of the closing of the contribution transaction. The Transaction Agreement closes on December 14, 2020. According to the Transaction Agreement and applicable securities law, Class B Shares issued to Adelia Shareholders are exchangeable for CLXPF Shares at the prevailing issue price.

  • How Does The Cerevel (CERE) Stock Price Increase By 52% Premarket?

    How Does The Cerevel (CERE) Stock Price Increase By 52% Premarket?

    The share price of Cerevel Therapeutics Holdings Inc. (CERE) rose 52.35% to trade at $19.15 at last check in premarket trading today. Cerevel stock closed on Monday at $12.57, down 3.01% from its previous close of $12.96. Volume of CERE stock traded was 0.35 million shares, which was higher than the average volume over the last three months, 302.67K shares. During the trading session, the CERE stock oscillated between $12.50 and $13.25.

    CERE had an earnings-per-share ratio of -2.41. Over the past five sessions, CERE has lost -8.78% of its value. On a month-to-month basis, CERE has lost -24.19% of its value. With a 50-day moving average of $13.85 CERE stock is above its 200-day moving average of $13.59. A RSI of 39.76 is currently being displayed on the CERE stock. After the topline results of a clinical trial, CERE stock has surged.

    The trial was held for what purpose?

    Cerevel’s goal is to uncover the mysteries of the brain with the goal of treating neurological diseases. A targeted neuroscience approach is used by CERE in its efforts to treat diseases combining expertise in neurocircuitry and receptor selectivity. CERE’s pipeline consists of five clinical-stage investigational therapies and several pre-clinical compounds that may be used to treat a variety of neurological diseases, including Parkinson’s, epilepsy, schizophrenia, and substance use disorders. CERE has its headquarters in Cambridge, Mass., and is actively researching new technology modalities through internal initiatives, external collaborations, or possible acquisitions.

    Cerevel today announced positive results from its Phase 1b clinical trial involving CVL-231, a muscarinic M4-selective positive allosteric modulator (PAM).

    • A 6 week period of continuous dosing of CVL-231 and a placebo showed similar discontinuation rates: 22% each. In summary, CERE’s CVL-231 was well tolerated by trial participants.
    • In addition, both the daily dose of 30 mg and the twice-daily dose of 20 mg demonstrated antipsychotic activity with overall well-tolerated profiles when compared to placebo.
    • The positive and negative syndrome scale (PANSS) total score decreased from baseline by 19.5 points and points for the placebo group decreased by 12.7 points, both statistically significant and clinically meaningful reductions.
    • The PANSS total score decreased by 17.9 points in the CERE group compared with the placebo group after taking 20 mg twice a day of CVL-231.

    What CERE plans to do next?

    In light of these encouraging results, Cerevel (CERE) is confident that a targeted muscarinic therapy that targets the M4 receptor can provide clinically meaningful benefits in schizophrenia treatment. CERE is going a long way towards unraveling how the muscarinic pathway can best be leveraged to better treat schizophrenia, in part by developing a drug that is several hundred times more selective for M4 receptors than M1, M2, M3, and M5.

  • CSX Corp. (CSX) Stock Plummets Ahead of Environmentally Friendly Agreement with Wabtec

    CSX Corp. (CSX) Stock Plummets Ahead of Environmentally Friendly Agreement with Wabtec

    CSX Corp. (CSX) stock prices were down by 0.62% as of the market closing on June 28th, 2021, bringing the price per share down to USD$95.32 at the end of the trading day. Subsequent pre-market fluctuations saw the stock fall by a massive 65.77%, bringing it down to USD$32.63.

    Partnership with Wabtec

    June 28th 2021 saw the company announce its partnership with Westinghouse Air Brake Technologies Corp, which would see the two collaborate to reduce their carbon footprint. This is to be achieved primarily be reducing greenhouse gas emissions resulting from company operations. The joint effort aims to facilitate a 37% reduction in greenhouse gas emissions by 2030.

    Details of Collaboration

    The companies will work together with a focus on the modernization of locomotives across CSX’s fleet. Advanced digital technologies will also be implemented to bolster fuel efficiency and reduce emissions for rail operations. The alliance will see CSX become the first railroad operator to make use of Wabtec’s Trip Optimizer Zero-to-Zero system, which will allow CSX to start trains from rest and stopping them automatically using various controls. The technology has helped railroads reduce their fuel consumption by more than 400 million gallons, while reducing CO2 emissions be more than 500,000 tons every year.

    Additional Considerations

    Furthermore, CSX will revitalize its fleet using Wabtec’s innovative Tier 4 switcher modernization program. The program will see 4 to 5 decade old locomotives being upgraded, with tier 0 non-emissions switchers being replaced by the latest Tier 4 platform from Wabtec. This technology facilitates a 90% reduction in emissions and provides a 20% improvement in fuel efficiency.

    Greenhouse Gas Emissions Reduced

    Wabtec’s FDL Advantage engine upgrade program will also be utilized in the modernizing of CSX’s fleet of locomotives. This program offers up to an additional 5% reduction in fuel consumption by offering improved injection control with a high-pressure common rail fuel system. The project aims to reduce CSX’s carbon footprint by up to 250 tons of CO2 per locomotive every year.

    About CSX

    The company provides rail, intermodal and rail-to truck transload services and solutions to customers spread out across a myriad of markets, including, but not limited to, energy, industrial, construction, agricultural, and consumer products. The company has linked more than 230 short-line railroads and more than 70 ocean, river, and lake ports with various major and minor population centers.

    Future Outlook for CSX

    Armed with its recent collaboration with Wabtec, which expands on the resources available to CSX, the company is poised to capitalize on the opportunities afforded to it through this venture. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • IovanceBiotherapeutics Inc. (NASDAQ: IOVA) stock plunged in the premarket trading session; here’s why

    IovanceBiotherapeutics Inc. (NASDAQ: IOVA) stock plunged in the premarket trading session; here’s why

    In the premarket trading session, IovanceBiotherapeutics Inc. (IOVA stock) had tumbled down to $25.42 making it a loss of-5.61% at last check of trading session. IOVA stock previously closed the session on Tuesday with a loss of -0.37% at $26.93. The IOVA stock previously traded on an average daily volume of 4.25 million for past 50 days however the current volume remained 2.68 million shares. In the past year up to date, IOVA stock had shed by -1.97% and had moved in the past week by 8.46%. In the past three and six month, the IOVA stock has shed -8.15%, and -45.65% respectively.

    Here’s what you need to know about IovanceBiotherapeutics Inc.

    IovanceBiotherapeutics Inc. is a clinical stage biotech company that focuses on the development and marketing of therapy and treatment that are novel and unique in nature to tackle the unmet need of the patients and healthcare workers. The therapy and treatment production platform on which the company basis its operations is specifically created for the commercialization of cancer immunotherapy products. The immune therapy products can help amplify patient’s immune system to get rid of cancer cells. The company has many investigational candidates programs in the pipeline, the lead product of which includes C-144-01 for treatment of metastatic melanoma and is currently ongoing for phase 2 clinical studies. Lifileucel C-144-04 is also a treatment for the persistent cervical cancer or recurrent, metastatic cervical cancer. The C-145-03 LN-145 product candidate is being tested for head and neck squamous cell carcinoma which is in metastatic or recurrent state. IovanceBiotherapeutics Inc. has strategic partnerships and benefits with various kinds of healthcare firms and biotech industries like having licensing agreement with H. Lee Moffitt cancer Center and collaboration agreements which include, Centre Hospitalier de I’Universite de Montreal, Novartis Pharma AG, Cellectis S.A., M.D Anderson Cancer Center and Ohio State University.

    The company was previously known as Lion Biotechnologies Inc. until June 2017 and was originated in 2007 with headquarter in San Carlos, California.

    The company has shown significant results for its clinical data of

    The company has overall shown promising results for the clinical data of its LN-145 therapy program which is a Tumor Infiltrating Lymphocyte (TIL) therapy specifically designed for patients with metastatic non-small cell lung cancer. These patients were selected and enrolled in the Cohort 3B of the ongoing basket study IOV-COM-202.

    The Overall Response Rate has shown that there is a significantly promising initial data for LN-145 for this rare patient population’s treatment. This patient population is urgently requiring a treatment to prolong survival in the second line non-small cell lung cancer treatment setting. The ORR was 21.4% and that rate at which the disease was controlled is known as DCR measured with a value of 64.3% for LN-145. The adverse effects observed by the administration of LN-145 dose showed that it was well within the limits of expected and consistent adverse event profile of non-myeloablative lymphodepletion and IL-2. The patients for this test were all given chemo therapy.IOVA stock claimed that further data will be extracted and demonstrated in the second half of 2021 at a medical meeting.

  • Why Did NOKBF Stock Plummet In Last Trading?

    Why Did NOKBF Stock Plummet In Last Trading?

    Nokia Corp (OTCPink: NOKBF) ended the last trading session at $5.4080 after losing -1.49% after which its market cap stood at $30.30B. Nokia stock traded 826.95K shares recently, less than its average daily volume of 912.89K. Furthermore, the NOKBF stock has been trading at a price range of $5.3600 and $5.5200 in that session. There are 5.60B outstanding shares of Pink Sheets compared to 4.64B float. NOKBF’s stock rose after the first trial of the intercontinental Terabit IP link.

    How did NOKBF conduct the trial?

    Nokia develops technology that makes the world more connected. NOKBF, a global leader in mobile, fixed and cloud networking, is a trusted partner for critical networks. Through its award-winning Nokia Bell Labs, NOKBF creates value through its long-term research and intellectual property. NOKBF strives to establish high standards of integrity and security to drive productivity, sustainability and inclusion for all.

    Vodafone Turkey, an operating unit within the Vodafone Group Plc, recently conducted an extensive trial with Nokia.

    • The NOKBF was conducting the trial to develop a clear-channel IP interface with a 1T (terabit) bandwidth for intercontinental communication.
    • Vodafone Turkey is attempting to scale up operations to effectively handle exponential growth in data traffic via its NOKBF trial project as part of its network modernization initiative.
    • In support of next-generation applications and access technologies, NOKBF’s 7950 XRS routers with terabit interfaces and NOKBF’s FP4 chipset enabled Vodafone Turkey to scale its IP network.
    • By carrying test traffic on Vodafone Turkey’s network, NOKBF’s FP4 terabit linecard demonstrated deployment readiness.
    • Furthermore, NOKBF terabit IP links simplify operations and reduce costs by avoiding the need to distribute high-capacity flows across multiple interfaces with lower rates used in link aggregation groups.
    • NOKBF offers a mobile infrastructure with multi-access capabilities that will help the operator adapt its transport infrastructure to changing industry demands.
    • NOKBF’s 7250 IXR interconnect router and FP4-based 7750 Service Router portfolio have already been deployed to deliver high-speed, low-latency 5G services to Vodafone Turkey.
    • NOKBF’s platforms support the features and protocols necessary to automate applications and optimize control over SDN.

    What else NPKBF is doing?

    Last week, Nokia (NOKBF) announced its next-generation ReefShark-powered AirScale massive MIMO antenna product line with 32TRX and 64TRX in addition to 8T8R radio heads with remote control. Additionally, NOKBF unveils its new SoC-based baseband plug-in cards that allow AirScale System Modules to scale up quicker. With its 84 Gbps throughput and 90,000 simultaneous connections, the NOKBF baseband module provides two-way communication for 90,000 users.

  • What Is Motivating The NMTR Stock Surge Premarket?

    What Is Motivating The NMTR Stock Surge Premarket?

    In premarket trading on Tuesday, 9 Meters Biopharma Inc. (NMTR) shares were up 3.51% at $1.18. At the end of last trading session, 9 Meters stock closed at $1.14, down 5.0%. A trading volume of 13.59 million shares was recorded by NMTR stock in the last trading session, much higher than the average daily volume of 4.2 million shares for the previous 50 days.

    In the past five days, NMTR’s stock has retreated -18.57%. Over the past month, the stock has fallen -10.24%. In the last three months, the price of NMTR stock has dropped by 13.64%, but has gained 32.71 percent so far this year. After joining the Russell index last session, NMTR stock has been rising.

    Has Russell index’s inclusion impacted NMTR?

    9 Meters Biopharma focuses on rare and unmet gastroenterology needs. NMTR will enroll vurolenatide, a proprietary long-acting GLP-1 agonist, in a Phase 2 clinical trial for short bowel syndrome (SBS). SBS is NMTR’s focal point due to its rarity and orphan status, as well as its Phase 3 tight junction regulator, which is being evaluated for signs and symptoms of non-responsive celiac disease.

    At the conclusion of the Russell US Indexes annual reconstitution, 9 Meters joined the Russell 3000 Index and the Russell 2000 Index for broad-market and small-cap companies, respectively.

    • On June 28, 2021, after the opening of the US equities markets, these updated indices took effect.
    • The Russell indexes are reconstituted annually and contain 4,000 of the largest US stocks as of May 7, 2021, ranked by market capitalization.
    • NMTR’s achievement of adding 9 Meters to this Russell Index is an indication of both the perseverance and achievement of the team as it continues to work towards becoming the treatment leader for rare, unmet gastroenterology disorders.
    • As NMTR gains momentum towards several milestones, inclusion in the Russell Indexes will increase its visibility among the international investment community.

    NMTR stepping towards its goals:

    9 Meters Biopharma (NMTR) recently initiated its Phase 2 trial of vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in adults with SBS. 9 Meters Biopharma is launching a Phase 2 trial of vurolenatide, which represents an important accomplishment for not only the company, but also for patients and families suffering from the devastating effects of SBS, including chronic diarrhea. As a result, NMTR may be a step closer to having longer-acting, more rapid-onset therapy and with a lower safety profile than any currently available therapy, potentially for the benefit of patients.

  • On What Basis Did ProBility (PBYA) Stock Skyrocketed Last Session?

    On What Basis Did ProBility (PBYA) Stock Skyrocketed Last Session?

    At the previous close, ProBility Media Corp [OTC: PBYA] stock surged 208.70% to $0.0071. Volume for ProBility stock averaged 2.43B versus 220.25M in the past 30 days. The price of PBYA stock fluctuated between $0.0001 and $0.0083 during the past 52 weeks. PBYA stock surged as its subsidiary initiated new training programs.

    What were the programs?

    Located in Coconut Creek, California, ProBility is an industrial education and training technology company that offers a variety of online and in person courses in various vocational fields. In order to facilitate the development of peak performing workers, PBYA has executed a disruptive strategy of defragmenting the education and training industry. Customers of PBYA range from individuals to small businesses to enterprise-level corporations.

    The North American Crane Bureau Group (NACB), a ProBility subsidiary, has launched new training programs for Marathon, BAE Systems and Tesla.

    • This training program consists of instruction for crane operators, inspectors, rigging personnel, and signal personnel as well as training for lift equipment trainers.
    • Moreover, these arrangements are intended to supplement training offered by PBYA across its entire corporate footprint.
    • With the relaxation of restrictions resulting from Covid-19, many corporations are scrambling to comply with OSHA safety specifications, crane inspections, and crane operator training and certification.
    • A new team of world class trainers has been hired by PBYA’s NACB in order to meet the demands of companies across the globe for these safety protocols.

    Shareholders of ProBility recently received an update regarding the company’s status.

    • PBYA worked to reduce overhead expenses in the first quarter of 2019.
    • PBYA decided to become an “alternative reporting” company.
    • In the aftermath of the acquisition, PBYA split its businesses into three companies: North American Crane Bureau, One Exam Prep and Disco Learning Media.
    • PBYA In addition, PBYA focused on eliminating non-profitable assets.
    • Reorganization efforts enabled PBYA to reduce both its revenue and operating expenses, but the decrease in expenses was so rapid that PBYA suffered a minimal operating loss in 2020.
    • Over the past few years, the PBYA has expanded its operations outside of its historical base of operations in Florida.
    • As part of its effort to reduce dependency on third-party vendors, PBYA is developing its own online and classroom-based training courses.
    • According to Securities Exchange Act Rule 15c-211 and OTC Markets Group, Inc Reporting Guidelines, PBYA intends to catch up with its filing obligations by September 28, 2021.

    How is PBYA working to grow?

    ProBility (PBYA) has been able to operate at pre-pandemic capacity through its subsidiaries, generating a profit in 2020 as a result of the lifting of pandemic restrictions. With the help of its debt repayment program and the consolidation of labor and other expenditures, PBYA continues to reduce its operating expenses.

  • Hollysys Automation Technologies Ltd. (HOLI) stock surged in the premarket trading session; why did this happen?

    Hollysys Automation Technologies Ltd. (HOLI) stock surged in the premarket trading session; why did this happen?

    In the premarket trading session, Hollysys Automation Technologies Ltd. (HOLI) stock had ramped up in the last trading session at a trade price of $16.19 which led to an increase of 13.93%. HOLI stock had previously closed the session at $14.21which was a gain of0.35% on Tuesday. The HOLI stock volume traded 0.13 million shares and in the past 50 days, the average trade volume has been 0.53 million. In the past year up to date, HOLI stock have risen by 7.81% and in the past week, HOLI stock jumped up by 2.45%.

    What you need to know about HollysysAutomationTechnologies Ltd.

    Hollysys Automation Technologies Ltd. is an electrical equipment and parts company that specifically focuses on the provision of automation solutions. The company has set up its operations in the People’s Republic of China, India, Southeast Asia, and the Middle East. The company has a portfolio of numerous industrial automation systems which are hardware centric products, actuators, software related logic control systems that are customizable and programmable. Hollysys Automation also provides software packages that comprise of real time management info system. These automation systems range from batch application package and operator training system to expansive proprietary nuclear power non-safety automation and control system. The company has clientele base of multiple industries which include railway, nuclear power, electronic, mechanical, and subway industries. The company was previously known as HLS Systems International Ltd until july 2009. Hollysys Automation was originated in 1993 and is based in Beijing, China.

    Considered acquisition by Buyer Consortium for outstanding shares at price of $17.10 per share

    The Buyer Consortium has planned and proposed to acquire Hollysys Automation Corporation Inc. The consortium consists of Mr. Shao Baiqing, Ace lead Profits Limited and CPE Funds Management Limited. The consortium has planned to provide shareholder who are large beneficial owners with a letter and a WHITE consent card. This is being transferred to the shareholders through banks and brokers. Furthermore, the consortium is showing guidance to shareholders who are registered on how to provide consent for the acquisition on the dedicated website.

    The details of the proposal suggest to the shareholders in the letter that the consortium wishes to gain all of the common outstanding and ordinary shares of the Hollysys Automation other than the ones already purchase by the consortium for the price of $17.10 per share. The amount will be transferred in cash. This offer resides a 37% premium on the share price as compared to 4th December 2020’s closing price.To proceed with the acquisition, the shareholders of the company, at least having 50% and more ownership will have to agree for this acquisition. This acquisition will then be mediated through BVI Business Companies Act 2004 which can override board’s power to invoke rights pursuant to HOLI stock’s existing “poison pill” for the acquired proposition.

  • PLx Pharma Inc. (PLXP) Stock Trends Lower as Preparations for VAZALORE Launch Continue

    PLx Pharma Inc. (PLXP) Stock Trends Lower as Preparations for VAZALORE Launch Continue

    PLx Pharma Inc. (PLXP) stock prices were down by 4.03% as of the market closing on June 28th, 2021, bringing the price per share down to USD$13.58 at the end of the trading day. Subsequent pre-market fluctuations saw the stock fall by a significant 5.30%, bringing it down to USD$12.86.

    Public Offering

    March 2021 saw the company complete an underwritten public offering wherein PLXP sold 8,924,700 shares of its common stock. Each share was priced at USD$8.00, with the offering having generated gross proceeds in the amount of USD$71.4 million, before the deduction of expenses related to the offering. The company plans to allocate the resources raised towards general corporate purposes, which include, but are not limited to, additions to working capital and capital expenditures.

    Revenue and R&D Expenses

    The company reported no revenue for the first quarter of fiscal 2021, as compared to the USD$2,523 reported for the first quarter of the prior year. The absence of revenue serves as the company’s baseline, with revenue in the 2020 period being attributable to operations under an award of a NIH grant, which concluded in the second quarter of 2020. Research and development expenses for the first quarter of 2021 were up to USD$1 million from the USD$0.5 million reported in the same quarter of the previous year. This difference is largely driven by increases in manufacturing-related activities for the company’s flagship VAZALORE.

    G&A Costs

    Q1 2021 saw the company report USD$2.6 million in general and administrative expenses, marginally higher than the USD$2.5 million reported for Q1 2020. The difference is largely driven by increased pre-launch marketing costs, as well as higher non-cash stock-based compensation. Lower compensation-related expenses and absence of travel costs because of the pandemic resulted in a partial offsetting of the initial year-over-year difference in G&A costs.

    FDA Approval

    The U.S Food and Drug Administration approved PLXP’s sNDA for its lead products, VAZALORE 325 mg and VAZALORE 81 mg. the company is allocating resources towards their commercialization as it strengthened its balance sheet by paying off the balance for a term loan that was due in February of 2021. The commercial launch of VAZALORE is scheduled for the third quarter of 2021

    Future Outlook for PLXP

    Armed with a consolidated balance sheet and the upcoming launch of its new VAZALORE products, PLXP is poised to expand its market footprint with the proliferation of its offerings. The company is poised to capitalize on the opportunities afforded to it and to continue its trajectory of success.Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • ZosanoPharma Corporation (ZSAN) stock plunged in the premarket trading here’s why

    ZosanoPharma Corporation (ZSAN) stock plunged in the premarket trading here’s why

    In the premarket trading session, ZosanoPharma Corporation (ZSAN) shares had plunged at last check by -3.27% to trade at the price of $0.977. ZSAN stock had previously closed the session on Tuesday while gaining 3.02% to close at $1.01. In the past 50 days, the ZSAN stock average volume of trading has been 2.44 million which is greater than today’s volume traded of 1.28 million shares. In the past year up to date has ZSAN shares rising by 24.23% and in the past week the shares have moved up by 9.30%. In the past three and six months, the stock has shed-12.17% and added 66.45%.

    What you need to know about ZosanoPharma Corporation

    ZosanoPharma Corporation is a biotechnology company that is specifically a clinical stage biopharma as well. ZSAN stock focuses on the production and provision of unique and novel treatments as well as therapeutics to meet the unmet needs of clients that are both health-workers and patients. The company has a platform where it develops therapeutics to reduce migraine for suffering patients along with other bioactive molecules which can work through using a transdermal microneedle system. The company’s lead investigative product candidate is used for the acute treatment of migraines. It is known as Qtrypta (M207) which is a proprietary formulation of zolmitriptan. The company was established in 2006 and is based in Fremont, California.

    ZosanoPharma Corporation is a leading biopharma that is specializing in the discovery and production of migraine treatments. Recent studies made by the ZosanoPharma have shown the effect of the Qtrypta on migraine suffering by reducing its frequency and pain. This holds a positive result for the potential of Qtrypta to be used as a long-term treatment solution for migraines.

    Zosano has made progress on its lead candidate Qtrypta’s long term study data

    The data obtained for this clinical trial was long-term data which is said to be published in the Journal of Headache and Pain. The safety and efficacy testing level of the trial suggested that it was tolerated consistently and showed no adverse effects while being tested in the Phase 2/3 ZOTRIP study.

    The long-term data of the study showcased that the pain frequency of the migraine had reduced for the patients observed in the study. The migraine attacks occurred on average 2 times per month for the selected patients and after taking Qtrypta dosage they obtaining relief while facing no serious side effects. The migraine attacks only lasted 2 hours after the Qtryota dose was administered, this result showed an efficacy of 81% in migraine attacks. Furthermore, the freedom of pain was for 44% of the attacks and had also reduced the worst and troubling symptoms of migraine attack by 62% of attacks.

    The administration of the dosage was majorly cutaneous application site where reactions were formed however these reactions were 95% mildly rated with 80% of the incidents of reaction resolved within 48 hours of application. This recent development has caused ZSAN stock shares to rise as it will with further milestones hopefully achieved in the future.